Cardinal Point Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.21M Buy
1,008
+67
+7% +$68.5K 0.07% 116
2026
Q1
$865K Buy
941
+285
+43% +$289K 0.05% 131
2025
Q4
$705K Buy
656
+11
+2% +$10.5K 0.05% 132
2025
Q3
$512K Sell
645
-66
-9% -$49.1K 0.04% 151
2025
Q2
$554K Buy
711
+294
+71% +$228K 0.04% 136
2025
Q1
$344K Buy
417
+12
+3% +$9.98K 0.03% 141
2024
Q4
$313K Buy
405
+2
+0.5% +$1.66K 0.05% 71
2024
Q3
$357K Hold
403
0.06% 64
2024
Q2
$365K Buy
403
+4
+1% +$3.2K 0.06% 59
2024
Q1
$310K Buy
399
+3
+0.8% +$2.13K 0.06% 60
2023
Q4
$231K Sell
396
-130
-25% -$75.9K 0.06% 61
2023
Q3
$283K Buy
+526
New +$271K 0.07% 58

Other funds holding LLY

Cardinal Point Capital Management's LLY Position: Q2 2026 in Review

Cardinal Point Capital Management increased its Eli Lilly (LLY) stake by 7.1% in Q2 2026, buying an estimated $68.5K and bringing the position to 1,008 shares worth $1.21M. The position accounts for 0.07% of the portfolio, ranked #116.

Cardinal Point Capital Management first reported a position in LLY in Q3 2023 and has held it in 12 quarters since. 1,842 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cardinal Point Capital Management held 1,008 shares of Eli Lilly worth $1.21M as of Q2 2026.
  • Cardinal Point Capital Management bought 67 Eli Lilly shares in Q2 2026, an estimated $68.5K.
  • Eli Lilly made up 0.07% of Cardinal Point Capital Management's portfolio in Q2 2026, its #116 holding.
  • Cardinal Point Capital Management first reported a position in Eli Lilly in Q3 2023 and has held it in 12 quarters since.
  • 1,842 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cardinal Point Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.